Exploring Clinical Study Experiences of People With Depression
Inside Depression Clinical Trials: Patient Experiences Shared While Undergoing Clinical Trials
1 other identifier
observational
500
1 country
1
Brief Summary
The study seeks to delve into the firsthand experiences of patients diagnosed with depression who partake in a separate clinical trial featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals. By joining this clinical trial, individuals have the unique opportunity to contribute to the betterment of future depression patients and play an active role in advancing medical research.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 30, 2023
CompletedFirst Posted
Study publicly available on registry
July 10, 2023
CompletedStudy Start
First participant enrolled
July 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2026
ExpectedJuly 10, 2023
June 1, 2023
1 year
June 30, 2023
June 30, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Number of patients who decide to participate in a depression clinical trial
3 months
Rate of patients who remain in depression clinical trial to trial completion
12 months
Eligibility Criteria
People with depression who are actively considering enrolling in an observational clinical trial, but have not yet completed enrollment and randomization.
You may qualify if:
- Patient has self-identified as planning to enroll in a clinical trial
- Patient has been diagnosed with depression
- Patient is a minimum of 18 years or older
You may not qualify if:
- Patient does not understand, sign, and return consent form
- Inability to perform regular electronic reporting
- Patient is pregnant
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Power Life Sciences
San Francisco, California, 94107, United States
Related Publications (3)
Fancourt D, Steptoe A, Bu F. Trajectories of anxiety and depressive symptoms during enforced isolation due to COVID-19 in England: a longitudinal observational study. Lancet Psychiatry. 2021 Feb;8(2):141-149. doi: 10.1016/S2215-0366(20)30482-X. Epub 2020 Dec 9.
PMID: 33308420BACKGROUNDDawson SR, Mallen CD, Gouldstone MB, Yarham R, Mansell G. The prevalence of anxiety and depression in people with age-related macular degeneration: a systematic review of observational study data. BMC Ophthalmol. 2014 Jun 12;14:78. doi: 10.1186/1471-2415-14-78.
PMID: 24923726BACKGROUNDMatison AP, Mather KA, Flood VM, Reppermund S. Associations between nutrition and the incidence of depression in middle-aged and older adults: A systematic review and meta-analysis of prospective observational population-based studies. Ageing Res Rev. 2021 Sep;70:101403. doi: 10.1016/j.arr.2021.101403. Epub 2021 Jul 8.
PMID: 34246793BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Michael B Gill
Power Life Sciences Inc.
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CROSSOVER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 30, 2023
First Posted
July 10, 2023
Study Start
July 1, 2024
Primary Completion
July 1, 2025
Study Completion (Estimated)
July 1, 2026
Last Updated
July 10, 2023
Record last verified: 2023-06